OFI Invest Asset Management Takes Position in Integer Holdings Co. (NYSE:ITGR)

OFI Invest Asset Management acquired a new stake in shares of Integer Holdings Co. (NYSE:ITGR) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 2,645 shares of the medical equipment provider’s stock, valued at approximately $338,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Loomis Sayles & Co. L P increased its position in shares of Integer by 3.0% during the third quarter. Loomis Sayles & Co. L P now owns 538,027 shares of the medical equipment provider’s stock valued at $69,943,000 after purchasing an additional 15,446 shares during the period. Jane Street Group LLC grew its position in Integer by 23.3% in the third quarter. Jane Street Group LLC now owns 151,397 shares of the medical equipment provider’s stock valued at $19,682,000 after acquiring an additional 28,572 shares during the period. Verition Fund Management LLC grew its position in Integer by 17.4% in the third quarter. Verition Fund Management LLC now owns 3,470 shares of the medical equipment provider’s stock valued at $451,000 after acquiring an additional 515 shares during the period. Versant Capital Management Inc grew its position in Integer by 98.4% in the fourth quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider’s stock valued at $49,000 after acquiring an additional 183 shares during the period. Finally, KBC Group NV grew its position in Integer by 83.3% in the fourth quarter. KBC Group NV now owns 1,598 shares of the medical equipment provider’s stock valued at $212,000 after acquiring an additional 726 shares during the period. 99.29% of the stock is currently owned by institutional investors.

Integer Trading Down 1.2 %

Shares of ITGR opened at $120.55 on Tuesday. The company has a quick ratio of 2.09, a current ratio of 2.95 and a debt-to-equity ratio of 0.62. Integer Holdings Co. has a 12-month low of $107.11 and a 12-month high of $146.36. The firm has a market capitalization of $4.05 billion, a PE ratio of 35.88, a price-to-earnings-growth ratio of 1.72 and a beta of 1.24. The stock’s fifty day simple moving average is $135.21 and its 200-day simple moving average is $132.99.

Integer (NYSE:ITGR) last issued its quarterly earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.46 by ($0.03). Integer had a net margin of 6.92% and a return on equity of 11.65%. The firm had revenue of $449.50 million for the quarter, compared to analyst estimates of $446.28 million. As a group, research analysts predict that Integer Holdings Co. will post 6.01 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Wells Fargo & Company reiterated an “overweight” rating and issued a $160.00 price target on shares of Integer in a research report on Tuesday, December 3rd. Benchmark upped their price target on Integer from $140.00 to $150.00 and gave the company a “buy” rating in a research report on Friday, February 21st. KeyCorp upped their price target on Integer from $144.00 to $154.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Citigroup boosted their price objective on Integer from $130.00 to $145.00 and gave the stock a “neutral” rating in a research note on Wednesday, December 11th. Finally, Oppenheimer lowered Integer from an “outperform” rating to a “market perform” rating in a research note on Friday, February 21st. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $147.67.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.